Dr Gwo-tzer Ho
Research Theme in a Nutshell: Science to medicine: Inflammatory triggers to tissue repair in IBD.
Research Theme in a Nutshell:
Science to medicine: Inflammatory triggers to Tissue Repair in IBD
My research is focused on two main questions:
1. What are the molecular factors that drive and maintain the abnormal musocal inflammation in Crohn's Disease (CD) and Ulcerative Colitis (UC)?
2. How do we translate this understanding to develop new, and to improve current, medical treatments for CD and UC?
- Bill Brownlee (Postdoctoral Scientist)
- Lisa Derr (MARVEL Trial Manager)
- Katherine Lewis (MARVEL Trial Support Officer)
- Broc Drury (Research Assistant)
- Thomas Fenton (Honorary CIR Fellow)
- Lena Fischer (Postdoctoral Scientist)
- Doirrean Gordon (iCASE PhD Student)
- Gareth-Rhys Jones (Senior Clinical Research Fellow)
- Rahul Kalla (Senior Clinical Research Fellow)
- Milly McAllister (Postdoctoral Scientist)
- Ross Porter (AF Research Fellow)
- Emily Thompson (PhD Student)
- Emma Ward (MUSIC trial manager)
- Jila Nazari (MUSIC Data Science Manager)
- Shaun Chuah (MUSIC Clinical Research Fellow)
- Beena Poulouse (MUSIC Clinical Research Nurse)
- Jon Rysdale (Patient Public Involvement Representative)
Edinburgh IBD Science Group
- Calum Bain (Centre for Inflammation Research, CIR)
- Susan Bodie (Business Development, BQ4)
- Jennifer Cartwright (CIR)
- David Dorward (Department of Pathology, RIE)
- Ian Dransfield (CIR)
- Emily Gwyer Findlay (CIR)
- Paul Henderson (RHSC)
- Kris Mcguire (CIR and Patient and Public Involvement Representative)
- Neil Mabbott (Roslin Institute)
- Adriano Rossi (CIR)
- Silke Salavati (Roslin Institute)
- Craig Stevens (Napier University)
- Emily Thomson (CIR and PhD representative)
- Marc Vendrell (CIR)
- David Wilson (Royal Hospital of Sick Children, RHSC)
- Chengcan Yao (CIR)
Our friendly group meets every 3-4 months to discuss collaborative ideas and scientific data. Please contact if interested in joining.
Crohn's disease (CD) and ulcerative colitis (UC) are common chronic inflammatory bowel diseases (IBD) with significant impact on morbidity, mortality and socio-economic costs. The global prevalence is increasing sharply with projected global disease burden of 20-30 million IBD cases by 2025. Present best therapies are based on the narrow principle of inhibiting downstream inflammatory pathways (eg, cytokines and inflammatory cell migration). Complete mucosal healing (total resolution of inflammation and restoration of full mucosal restitution) however, is achieved only in 50% in our best treatment. My work is focused on identifying and developing novel therapeutic approaches in IBD.
My overarching research aim is to translate new knowledge of immune and inflammatory mucosal mechanisms into new therapeutic approaches in IBD.
I work very closely with dedicated IBD clinicians, biologists, immunologists and drug development teams with a strong focus on direct studies on human IBD along with in vivo colitis work. Major mechanistic themes are:
- Gut derived mucosal damage-associated molecular patterns (DAMPs)
- Mitochondrial dysfunction and ROS-signalling
- Metabolic programing of the mucosal immune response
- Active reparative mechanisms with novel targets focused on inflammatory monocytes-macrophage and T-cell trafficking.
Find out more by watching our Let's Talk About Health public lecture from 2020:
- Video: Healing the damaged gut in inflammatory bowel diseases
- A recording of the Let's Talk About Health public lecture given on 19 February 2020, talking about the perspectives of a medical researcher, IBD patient and PhD student on current IBD research at the Centre for Inflammation Research.
Our current projects
GI-DAMPs (CCUK-Genentech-Guts Charity UK): We seek to understand how mitochondrial DAMPs are released and how they activate the downstream inflammatory pathways (TLR9 and FPR1). We aim to find new therapeutic targets to accelerate the resolution of inflammation as an adjunct to current immune-suppressive treatments (@GI-DAMPs).
MARVEL (Jon Moulton Foundation): Mitochondrial antioxidant therapy to resolve inflammation in Ulcerative colitis (MARVEL) trial, a UK-wide randomized double-blind placebo-controlled trial using oral MitoQ (from February 2020). This builds directly from our primary scientific work; we are very excited to translate our science with this Phase II trial to test the potential of mitochondrial protective therapy in human IBD (@MarvelTrial).
MiniMARVEL: Together with David Wilson (Royal Sick Childrens Hospital, Edinburgh), we are setting up a European-wide randomized controlled trial using MitoQ in paediatric and early-onset Ulcerative Colitis.
MUSIC (Helmsley Charitable Trust): Mitochondrial DAMPs as mechanistic biomarkers of mucosal inflammation in Crohn's disease. We are generating a large deep endophenotyped IBD prospective cohort with longitudinal analysis of mucosal healing (from February 2020). Based on this, we aim to translate DAMPs signals as stratifying approach to future new therapies in IBD.
Defining gut macrophage heterogeneity in CD (Wellcome Trust/ECCO): Using transcriptomics and epigenomic profiling approach as the first step to define the monocyte-macrophage populations during inflammation and resolution in Crohn's disease.
Pro-R in IBD (Chief Scientist Office/MRC/ERC): Working together with Emily Findlay (T-cell immunologist), Calum Bain (macrophage biologist), Adriano Rossi (deputy director of Centre for Inflammation Research), Ian Dransfield (leukocyte biologist) and Marc Vendrell (translational chemist), we have a program of inter-connected studies that are focused at accelerating repair in the IBD gut.
IBDIMAGE - Disruptive fluorescent technologies for inflammatory bowel disease. Lead: Dr Marc Vendrell. Developing novel biomarker technologies for IBD.
I trained in Medicine in Glasgow (MBChB 1997 and MRCP 2000), and moved to Edinburgh to undertake my PhD with Jack Satsangi (2000-2003). I completed my specialty training in gastroenterology and internal medicine in Edinburgh (2003-2008) and was awarded an MRC Clinician Scientist Fellowship award (2009-2015). During this time, I trained under Balfour Sartor in University of North Carolina, Chapel Hill, USA (2009-2010) focusing on mucosal immunology in IBD, and moved to the MRC Centre for Inflammation Research in 2011 to establish my laboratory here.
I continue to care for individuals with IBD at the Western General Hospital and I lead the Edinburgh IBD Science Group (@Edin_IBDScience), a multidisciplinary group of researchers and scientists in Edinburgh with an aim to translate our scientific work into new treatments in IBD.
Honours and Awards
- 2016 Fellow of Royal College of Physicians (Edinburgh)
- 2009 Medical Research Council Clinician Scientist Fellowship
- 2008 United European Gastroenterology Rising Star Award
- 2007 British Society of Gastroenterology CORE Research Prize
- 2006 European Crohn's and Colitis Organization (ECCO) Researcher Award for UK
- 2004-6 American Gastroenterology Association Abstracts of Distinction (3 awards)
- Dr Ray Boyapati (2015-2017): Consultant Gastroenterologist, Melbourne
- Dr Arina Tamborska (2016): Academic Fellow, King’s College London
- Professor Adriano Rossi/David Dorward
- Professor Ian Dransfield/Emily Findlay
- Dr Marc Vendrell
- Dr Robert Gray
- Dr Calum Bain
- Professor David Wilson
Professor William Agace, Lund University, Denmark
- Professor Balfour Sartor: University of North Carolina, Chapel Hill, USA
- Professor Jack Satsangi: University of Oxford, UK
Sources of Funding
- Crohn's Colitis UK
- Guts Charity UK
- Jon Moulton Foundation
- Wellcome Trust
- European Crohn's and Colitis Organisation (ECCO)
- Medical Research Society